Rv3628 |
|
Vaxjo ID |
258 |
|
Vaccine Adjuvant Name |
Rv3628 |
|
Alternative Names |
Rv3628 Soluble class I pyrophosphatase from Mycobacterium tuberculosis |
|
Adjuvant VO ID |
VO_0005745
|
|
Description |
Rv3628 is a soluble protein from Mycobacterium tuberculosis that acts as a TLR2 agonist, activating dendritic cells (DCs) and enhancing antigen presentation. It is investigated as an immunoadjuvant to promote Th1-type antitumor immune responses. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Structure |
Soluble protein enzyme Belongs to class I pyrophosphatases (PPase) |
|
Molecular Weight |
~20 kDa |
|
Storage |
Stored at −80°C after purification and endotoxin removal. |
|
Preparation |
Recombinant expression in E. coli Purification using Ni-NTA resin Endotoxin removal via polymyxin B agarose column |
|
Dosage |
2.5 mg/kg in mice (subcutaneous or intravenous) Combined with 2.5 mg/kg antigen (e.g., OVA or tumor lysate) |
|
Function |
Tumor antigens (Ags) are weakly immunogenic and elicit inadequate immune responses, thus induction of antigen-specific immune activation via the maturation of dendritic cells (DCs) is a strategy used for cancer immunotherapy. In this study, we examined the effect of Rv3628 from Mycobacterium tuberculosis (Mtb) on activation of DCs and anti-tumor immunity in vivo. |
|
Safety |
Safe in mice |
| References |
Wu et al., 2021: Wu J, Yang H, Xu JC, Hu Z, Gu WF, Chen ZY, Xia JX, Lowrie DB, Lu SH, Fan XY. Mycobacterium tuberculosis Rv3628 isan effective adjuvant via activationof dendritic cells for cancer immunotherapy. Molecular therapy oncolytics. 2021; 23; 288-302. [PubMed: 34786473].
|
